560 related articles for article (PubMed ID: 27911230)
21. Bromodomain Histone Readers and Cancer.
Jain AK; Barton MC
J Mol Biol; 2017 Jun; 429(13):2003-2010. PubMed ID: 27890782
[TBL] [Abstract][Full Text] [Related]
22. Advancements in the Development of non-BET Bromodomain Chemical Probes.
Clegg MA; Tomkinson NCO; Prinjha RK; Humphreys PG
ChemMedChem; 2019 Feb; 14(4):362-385. PubMed ID: 30624862
[TBL] [Abstract][Full Text] [Related]
23. Cancer-associated polybromo-1 bromodomain 4 missense variants variably impact bromodomain ligand binding and cell growth suppression.
Bursch KL; Goetz CJ; Jiao G; Nuñez R; Olp MD; Dhiman A; Khurana M; Zimmermann MT; Urrutia RA; Dykhuizen EC; Smith BC
J Biol Chem; 2024 Apr; 300(4):107146. PubMed ID: 38460939
[TBL] [Abstract][Full Text] [Related]
24. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.
Hewings DS; Wang M; Philpott M; Fedorov O; Uttarkar S; Filippakopoulos P; Picaud S; Vuppusetty C; Marsden B; Knapp S; Conway SJ; Heightman TD
J Med Chem; 2011 Oct; 54(19):6761-70. PubMed ID: 21851057
[TBL] [Abstract][Full Text] [Related]
25. Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.
Hewings DS; Rooney TP; Jennings LE; Hay DA; Schofield CJ; Brennan PE; Knapp S; Conway SJ
J Med Chem; 2012 Nov; 55(22):9393-413. PubMed ID: 22924434
[TBL] [Abstract][Full Text] [Related]
26. Functional Roles of Bromodomain Proteins in Cancer.
Boyson SP; Gao C; Quinn K; Boyd J; Paculova H; Frietze S; Glass KC
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298819
[TBL] [Abstract][Full Text] [Related]
27. Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.
Romero FA; Taylor AM; Crawford TD; Tsui V; Côté A; Magnuson S
J Med Chem; 2016 Feb; 59(4):1271-98. PubMed ID: 26572217
[TBL] [Abstract][Full Text] [Related]
28. Selective recognition of acetylated histones by bromodomains in transcriptional co-activators.
Hassan AH; Awad S; Al-Natour Z; Othman S; Mustafa F; Rizvi TA
Biochem J; 2007 Feb; 402(1):125-33. PubMed ID: 17049045
[TBL] [Abstract][Full Text] [Related]
29. Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases.
Padmanabhan B; Mathur S; Manjula R; Tripathi S
J Biosci; 2016 Jun; 41(2):295-311. PubMed ID: 27240990
[TBL] [Abstract][Full Text] [Related]
30. Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching.
Philpott M; Rogers CM; Yapp C; Wells C; Lambert JP; Strain-Damerell C; Burgess-Brown NA; Gingras AC; Knapp S; Müller S
Epigenetics Chromatin; 2014; 7():14. PubMed ID: 25097667
[TBL] [Abstract][Full Text] [Related]
31. Targeting Cancer Cells with BET Bromodomain Inhibitors.
Xu Y; Vakoc CR
Cold Spring Harb Perspect Med; 2017 Jul; 7(7):. PubMed ID: 28213432
[TBL] [Abstract][Full Text] [Related]
32. Bromodomains: A novel target for the anticancer therapy.
Gokani S; Bhatt LK
Eur J Pharmacol; 2021 Nov; 911():174523. PubMed ID: 34563497
[TBL] [Abstract][Full Text] [Related]
33. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
[TBL] [Abstract][Full Text] [Related]
34. Chemical Proteomic Profiling of Bromodomains Enables the Wide-Spectrum Evaluation of Bromodomain Inhibitors in Living Cells.
Li X; Wu Y; Tian G; Jiang Y; Liu Z; Meng X; Bao X; Feng L; Sun H; Deng H; Li XD
J Am Chem Soc; 2019 Jul; 141(29):11497-11505. PubMed ID: 31246451
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.
Chaidos A; Caputo V; Karadimitris A
Ther Adv Hematol; 2015 Jun; 6(3):128-41. PubMed ID: 26137204
[TBL] [Abstract][Full Text] [Related]
36. Effect of BET Missense Mutations on Bromodomain Function, Inhibitor Binding and Stability.
Lori L; Pasquo A; Lori C; Petrosino M; Chiaraluce R; Tallant C; Knapp S; Consalvi V
PLoS One; 2016; 11(7):e0159180. PubMed ID: 27403962
[TBL] [Abstract][Full Text] [Related]
37. Disrupting Acetyl-lysine Interactions: Recent Advance in the Development of BET Inhibitors.
Zhang F; Ma S
Curr Drug Targets; 2018; 19(10):1148-1165. PubMed ID: 29189147
[TBL] [Abstract][Full Text] [Related]
38. Targeting Histone Acetylation: Readers and Writers in Leukemia and Cancer.
Benton CB; Fiskus W; Bhalla KN
Cancer J; 2017; 23(5):286-291. PubMed ID: 28926429
[TBL] [Abstract][Full Text] [Related]
39. The bromodomain: from epigenome reader to druggable target.
Sanchez R; Meslamani J; Zhou MM
Biochim Biophys Acta; 2014 Aug; 1839(8):676-85. PubMed ID: 24686119
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
